711-1 Angiopeptin Significantly Improves Twelve Months Event Free Survival Following PTCA in a Randomized Double Blind Study  by Emanuelsson, Håkan et al.
80A ABSTRACTS lACC February 1995
Actuarial follow-up event rates:
Events 6-months
- Death (%) 5
-MI(%) 7
- CABG (%) 7
- PTCA(%} 6
- Event-free survival (%) 75
12-months
8
8
9
8
67
24-months
14
8
12
12
55
revascularization (PTCA or CABG). Revascularization data were collected on
both the original target vessel and non-target vessels. The event free survival
curve for all patients shows Angiopeptin to significantly (p = 0.046) decrease
the clinical events compared to placebo. If non-target vessels are included
the improved event free survival is maintained (p = 0.0421. This significant
decrease in clinical event rate was already obtained at 6 months (p = 0.034,
odds ratio = 0.66, 95% confidence interval 0.45-0.97).
Event-free survival ~ freedom from death, MI. CABG or PTCA TVR TVR + non-TVR
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Recombinant-hirudin (CGP 39 393) Reduces the
Incidence of Major Adverse Cardiac Events,
Reported within the First 96 Hours Post-Angioplasty
in Unstable Patients (Braunwald Classification)
Pre-treated by Heparin
Patrick W Serruys, Keith AA Fox, Jean-Paul R. Herrman, Doris Bach 1,
Philip Close 1, Jaap W Deckers, HELVETICA investigators. Thoraxcentrum. Erasmus
University, Rotterdam, The Netherlands; 1 Ciba-Geigy Ltd, Bas/e, Switzerland
Background: r-Hirudin (Hir). an antithrombin may prevent thrombosis post
angioplasty thereby reducing early thrombotic events and late restenosis.
Methods: 1141 patients were prospectively randomized to 1) 10,OOOIU
heparin bolus + 15 IU/kg/hr iv heparin 24 hrs + sc placebo (HEP), or 2) Hir 40
mg bolus + 0.2 mg/kg/hr Hir iv 24 hrs + sc placebo (HIR Lv.), or 3) Hir 40 mg
bolus + 0.2 mgjkg/hr Hir iv 24 hrs + 40 mg Hir sc bid for 3 days (HIR Lv. +
s.c). All patients had unstable angina pectoris. Study treatment started just
prior to angioplasty.
Secondary endpoint: incidence of early (:s96 hrs) major adverse cardiac
events. Randomization was stratified for presence or absence of heparin pre-
treatment ("ON" vs. "OFF" heparin):
This significant effect of Angiopeptin in decreasing clinical events in pa-
tients undergoing PTCA is maintained at one year.
RAVES Non-RAVES Pvalue
Vascular/bleeding complications (%) 31 19.1 004
TransfusionlSurgical repair (%) 0/0 24.0/93 0002/0.1
Subacute thrombosis (%) 0 13 1.0
In-hospital Complieations (%): 0/0/0/0 13/0/0/13 1.0/-1-11.0
Death/MI/CABG/Repeat fTTCA
Length of stay (days) 43±20 82 ± 4.9 <0.0001
Costs ($) 8,734 ± 2,238 14,182 ± 6,938 <00001
Stent (S) placement in the treatment of saphenous vein graft (SVG) lesions
has been limited by increased bleeding complications and prolonged hos-
pital stay due to intense anticoagulation after procedure. Intravascular ultra-
sound (IVUS) guided S implantation with .B.educed 8nticoagulation (no hep-
arin or coumadin post procedure) VEin graft.§.tent trial (RAVES) was designed
to address these issues. To assess the economic impact of this novel S place-
ment technique, we compared the in-hospital complications and costs in 33
RAVES pts with 77 pts who underwent standard (Non-RAVESI S deployment
for SVG lesions. Enrollment criteria, pt demographics and pre-treatment an-
giographic findings were similar between the 2 groups. Vascular/bleeding
complications = hematoma with> 15% drop in hematocrit, A-V fistula, pseu-
doaneurysm, retroperitoneal bleed, and gastrointestinal bleed.
Conclusion: Similar to PTCA in SVG lesions and in contrast to stents in
native coronaries, patients with stents in SVG's exhibit a disappointing attri-
tion in late clinical outcomes beyond one year, Both increasing mortality and
repeat revascularization procedures contribute to the 2-year 55% event-free
survival. We surmise that further deterioration at the stent site (Le, "late"
restenosis), increasing non-TLR events, and less favorable baseline charac-
teristics are responsible for these findings.
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1710-61 Economic Impact of Reduced Anticoagulation After
Saphenous Vein Graft Stent Placement
s, Chiu Wong, Jeffrey J. Popma, Ya Chien Chuang, Gary S, Mintz, Lowell F Satler,
Kenneth M. Kent, Augusto D, Pichard, Mun K. Hong, Theresa A. Bucher,
Kathi Donovan, Kathy Morgan, Alan Merritt, David Kaufman, Martin B. Leon.
Washington Hospital Center, Washington, DC
There were no out-of-hospital ischemic complications reported up to 1
month (vulnerable period for subacute thrombosis) after procedure in both
groups.
/n Conclusion: IVUS guided S implantation with reduced anticoagulation
resulted in marked reduction in bleeding events and no increase in procedu-
ral or 30-day complications, The hospital length of stay was significantly re-
duced in the RAVES pts with substantial cost saving (38.4%) compared with
Non-RAVES pts. If this observation holds true in a larger cohort, S placemHnt
with reduced anticoagulation should be the treatment of choice for SVG le-
sions.
Adjunctive Therapy and Outcome With PTeA
Monday, March 20, 1995,2:00 p.m.-3:30 p.m.
Ernest N. Morial Convention Center, Room 102
Results HEP HIR i.v. HIR i.v. + s.c.
"ON" "OFF" "ON" "OFF" "ON" "OFF"
N= 115 267 110 271 110 269
Any Event % 174 82 64 8.5 64 52
Death % 09 04
Ml% 70 2.2 2.7 3.7 4.6 15
CABG% 70 4.5 3.6 37 18 2.2
Re-PTCA % 2.6 1.1 1.1 1.5
Conclusion: In patients with unstable angina who were receiving heparin
at the time of randomization, hirudin i.v. for 24 hours, with or without hirudin
s.c, for 72 hrs, substantially reduces the incidence of major adverse cardiac
events encountered during the first 96 hrs following PTCA, when compared
to heparin as anticoagulant (-63%,6.4% vs 17.4%, Chi square p = 0.007).
This favourable effect is obtained without a significant increase in major
bleeding complications (HEP 6.2%, HIR Lv. 5.5%, HIR Lv. + s.c. 7.6%).
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~ Angiopeptin Significantly Improves Twelve Months
Event Free Survival Following PTCA in a Randomized
Double Blind Study
H~kan Emanuelsson, Kevin J. Beatt. Jens-Peder Bagger, Raphael Balcon,
Juhani Heikkila, Jan Piessens, Marc Schaeffer, Harry Suryapranata, Marie L. Foegh,
European Angiopeptin Study Group. Henri Beaurour Institute, Washington, D.C.
Patients (n = 553) undergoing coronary balloon angioplasty in 18 European
centers were randomized to receive a five-day continuous s.c. infusion of
either placebo or Angiopeptin (6 mg/daYI beginning the day prior to PTCA.
The inclusion criteria were broad and only patients with a Q-wave infarction
within the last 4 weeks prior to PTCA were excluded. The primary endpoint
for 12 months outcome was the composite of death, non-fatal MI or repeat
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A Multicenter, Randomized, Double-Blind Pilot Trial
of Standard Versus Low Dose Weight-Adjusted
Heparin in Patients Treated with the Platelet GP
lib/ilia Receptor Antibody c7E3 During Percutaneous
Coronary Revascularization
A Michael Lincoll, James E. Tcheng, Theodore A. Bass, Jeffrey J. Popma, Paul
S. Teirstein, Neal S, Kleiman, Harlan F. Weisman, Maura H. Musco, Catherine
F Cabot, Lisa G. Berdan, Robert M. Califf, Eric J. Topol, PROLOG Investigators.
Cleveland Clinic Foundation, Cleveland, OH; Duke University, Durham, NC
Blockade olthe platelet GP lib/lila receptor by the monoclonal antibody c7E3
during high-risk coronary intervention reduced the 30-day endpoint of death,
MI, or urgent revascularization by 35% in the EPIC trial, but was accompa-
nied by an increase in the rate of major bleeding. In EPIC, heparin was ad-
